Neurodegenerative dementias are progressive diseases that cause neuronal network breakdown in different brain regions often because of accumulation of misfolded proteins in the brain extracellular matrix, such as amyloids or inside neurons or other cell types of the brain. Several diagnostic protein biomarkers in body fluids are being used and implemented, such as for Alzheimer’s disease. However, there is still a lack of biomarkers for co-pathologies and other causes of dementia. Such biofluid-based biomarkers enable precision medicine approaches for diagnosis and treatment, allow to learn more about underlying disease processes, and facilitate the development of patient inclusion and evaluation tools in clinical trials. When designing studies to discover novel biofluid-based biomarkers, choice of technology is an important starting point. But there are so many technologies to choose among. To address this, we here review the technologies that are currently available in research settings and, in some cases, in clinical laboratory practice. This presents a form of lexicon on each technology addressing its use in research and clinics, its strengths and limitations, and a future perspective.

, , , , , ,
Molecular & Cellular Proteomics

Teunissen, C., Kimble, L., Bayoumy, S., Bolsewig, K., Burtscher, F., Coppens, S., … Abeln, S. (2023). Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias. Molecular & Cellular Proteomics, 22(10), 100629:1–100629:19. doi:10.1016/j.mcpro.2023.100629